First Time Loading...

Cumberland Pharmaceuticals Inc
NASDAQ:CPIX

Watchlist Manager
Cumberland Pharmaceuticals Inc Logo
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Watchlist
Price: 1.68 USD -6.15%
Updated: Mar 29, 2024

Intrinsic Value

CPIX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. [ Read More ]

The intrinsic value of one CPIX stock under the Base Case scenario is 3.95 USD. Compared to the current market price of 1.68 USD, Cumberland Pharmaceuticals Inc is Undervalued by 57%.

Key Points:
CPIX Intrinsic Value
Base Case
3.95 USD
Undervaluation 57%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Cumberland Pharmaceuticals Inc

Backtest CPIX Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CPIX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Revenue Up, Caldolor Expands, Trials Progress
2023-Q3 Earnings Call

Revenue Up, Caldolor Expands, Trials Progress

In Q3, the company's FDA-approved brands garnered $10.1 million in revenue, bringing the year-to-date total to $30.2 million, with adjusted earnings reaching $4.2 million. Sales of Vibativ increased by 13%, and Kristalose, their leading product, saw an 8% uptick. Caldolor, now approved for infants, and with a new Medicare reimbursement expected in 2025, contributed to an 8% sales increase in its category. Despite challenges, Sancuso's transition is complete and has brought in $12.2 million in cash contributions. The company also emphasized its progress in Phase II clinical trials for ifetroban and the completion of Sancuso's transition to Cumberland's operations. Financial assets stand at $88 million, with an available revolving credit line of up to $25 million, and a share repurchase program has been active.

Financials

Balance Sheet Decomposition
Cumberland Pharmaceuticals Inc

Current Assets 35.7m
Cash & Short-Term Investments 18.3m
Receivables 9.8m
Other Current Assets 7.6m
Non-Current Assets 46.1m
PP&E 7m
Intangibles 23.5m
Other Non-Current Assets 15.5m
Current Liabilities 28m
Accounts Payable 14m
Accrued Liabilities 348.1k
Other Current Liabilities 13.6m
Non-Current Liabilities 24.2m
Long-Term Debt 12.8m
Other Non-Current Liabilities 11.4m
Efficiency

Earnings Waterfall
Cumberland Pharmaceuticals Inc

Revenue
39.6m USD
Cost of Revenue
-6.1m USD
Gross Profit
33.5m USD
Operating Expenses
-39.7m USD
Operating Income
-6.2m USD
Other Expenses
-68.5k USD
Net Income
-6.3m USD

Free Cash Flow Analysis
Cumberland Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CPIX Profitability Score
Profitability Due Diligence

Cumberland Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Declining ROIC
35/100
Profitability
Score

Cumberland Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

CPIX Solvency Score
Solvency Due Diligence

Cumberland Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
37/100
Solvency
Score

Cumberland Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CPIX Price Targets Summary
Cumberland Pharmaceuticals Inc

Wall Street analysts forecast CPIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CPIX is 8.5 USD .

Lowest
Price Target
Not Available
Average
Price Target
8.5 USD
406% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CPIX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CPIX Price
Cumberland Pharmaceuticals Inc

1M 1M
-21%
6M 6M
-11%
1Y 1Y
-16%
3Y 3Y
-45%
5Y 5Y
-71%
10Y 10Y
-63%
Annual Price Range
1.68
52w Low
1.43
52w High
2.3
Price Metrics
Average Annual Return -9.87%
Standard Deviation of Annual Returns 54.42%
Max Drawdown -79%
Shares Statistics
Market Capitalization 23.7m USD
Shares Outstanding 14 176 500
Percentage of Shares Shorted 0.3%

CPIX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cumberland Pharmaceuticals Inc Logo
Cumberland Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

23.7m USD

Dividend Yield

0%

Description

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. The company is headquartered in Nashville, Tennessee and currently employs 83 full-time employees. The company went IPO on 2009-08-11. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of constipation; and Omeclamox-Pak for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Its brands also include RediTrex injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Sancuso transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ injection.

Contact

TENNESSEE
Nashville
2525 W End Ave Ste 950
+16152550068.0
http://www.cumberlandpharma.com/

IPO

2009-08-11

Employees

83

Officers

Founder, Chairman, President & CEO
Mr. A. J. Kazimi MBA
Chief Financial Officer
Mr. John Michael Hamm
Executive VP of National Accounts & Chief Compliance Officer
Mr. James Lowrance Herman
Senior VP of Administrative Services & Corporate Secretary
Ms. Jean W. Marstiller
Vice President of Sales & Marketing
Mr. Chris T. Bitterman
Managing Director
Mr. Adam S. Mostafa
Show More
Vice President of Organizational Development
Mr. Todd M. Anthony
Senior Corporate Relations Associate
Ms. Erin Smith Gull
Show Less

See Also

Discover More
What is the Intrinsic Value of one CPIX stock?

The intrinsic value of one CPIX stock under the Base Case scenario is 3.95 USD.

Is CPIX stock undervalued or overvalued?

Compared to the current market price of 1.68 USD, Cumberland Pharmaceuticals Inc is Undervalued by 57%.